MedBen Rx
  • About Us
  • Genomic Testing
  • Resources
    • MedBen Rx Blog
    • Online Services & Forms
  • Contact Us
  • MedBen Access
  • MedBen.com
Select Page

A High-Value Approach to Lowering Rx Spend

Oct 30, 2023 | Appropriateness Solutions, Comparative Effectiveness, Drug costs, MedBen Rx, Pharmacies, Prescription drugs, Research

MedBen Rx’s expanded pharmacy solutions offer a variety of ways to reduce your prescription drug spend… including appropriateness solutions that use clinical-based research to recommend the most effective drugs to your plan members. Comparative...

Lower Specialty Drug Costs with MedBen Rx Access Solutions

Mar 6, 2023 | Access solution, Access solutions, MedBen Rx, Medicare, Research, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs

Employers pay up to 30 times as much for specialty drugs than Medicare does, new research finds. According to the JAMA Health Forum, for the 10 most commonly used specialty drugs, employer-sponsored insurance (ESI) plans paid prices up to 3,350%...

Comparative Effectiveness Silences the Drug Ad Hype

Feb 21, 2023 | Comparative Effectiveness, MedBen Rx, Research, Rx Advertising, Rx Costs, Rx prices, Rx Spending, TruDataRx

Drug companies spend $6 billion per year on direct-to-consumer ads with the goal of getting patients to ask their doctors to prescribe drugs that, in many instances, cost substantially more but are less effective than their current medications. And with no comparative...

Categories

  • 340B
  • Access solution
  • Access solutions
  • Acquisition Cost Index (ACI)
  • Affordable Care Act
  • Anniversaries
  • Announcements
  • Appropriateness Solutions
  • Avande
  • Average Wholesale Price
  • Benefits Advisory Conference
  • Benefits preservation
  • Biologics
  • Biosimilar
  • Brand Name Drugs
  • Brian Fargus
  • Cancer
  • Caroline Fraker
  • Case Study
  • Cholesterol
  • Claims
  • Client Report
  • Comparative Effectiveness
  • Compliance
  • Consolidated Appropriations Act of 2021 (CAA)
  • Cost Plus
  • Cost Plus Pricing
  • Cost projections
  • Cost Savings
  • Diabetes
  • Discounts
  • Doug Freeman
  • Drug costs
  • Drug makers
  • Drug marketing
  • Drug reimportation
  • Evidence-based research
  • Federal Trade Commission (FTC)
  • Food and Drug Administration (FDA)
  • Formularies
  • Fraud
  • Gene therapy
  • Generic Drugs
  • Genetic testing
  • Genomics
  • GLP-1s
  • Government
  • Guarantees
  • Health and Human Services
  • Health systems
  • Heart medications
  • History
  • Humalog
  • Humira
  • Idacio
  • Inflation
  • Kurt Harden
  • Lawsuits
  • Legislation
  • Limited Use HRA
  • Lobbying
  • Luke Burchard
  • MDMA (ecstasy)
  • MedBen
  • MedBen Access
  • MedBen Basics
  • MedBen Board of Directors\
  • MedBen employees
  • MedBen Rx
  • MedBen Rx Advocate
  • MedBen Rx Alliance
  • MedBen Rx News
  • MedBen University
  • Medicare
  • Mobile app
  • Mounjaro
  • News
  • Nutrigenomics
  • Online Services
  • Opinions
  • Outcomes
  • Overprescribing
  • Own Use
  • Ozempic
  • Patient advocacy program
  • Perigon Pharmacy 360
  • Pharmacies
  • Pharmacogenomics
  • Pharmacy Benefits Manager (PBM)
  • Pharmacy Services Administrator (PSA)
  • Precision medicine
  • Prescription drugs
  • Prescription Portal
  • Pricing solutions
  • Psychedelic drugs
  • Rebates
  • Regulatory
  • Reporting
  • Research
  • Rx Advertising
  • Rx Costs
  • Rx Facts
  • Rx prices
  • Rx Spending
  • RxDC report
  • Savings
  • Specialty Drugs
  • Spread Pricing
  • State legislation
  • Statins
  • Stelara
  • Study
  • Surveys
  • Transparency
  • Trend
  • TruDataRx
  • Trulicity
  • Value
  • Ventegra
  • Wegovy
  • Weight loss
  • Weight loss drugs
  • Weight management
  • Wellness
  • White paper
  • Zepbound
  • About Us
  • Contact Us
  • Blog
  • Online Services
  • MedBen Access
  • Sitemap
  • Privacy
  • MedBen.com

Sign Up for our Newsletter

  • This field is for validation purposes and should be left unchanged.
© 2025 MedBen Rx. All rights reserved.